Iovance appoints Dan Kirby as Chief Commercial Officer to lead Amtagvi launch expansion

IOVANCE BIOTHERAPEUTICS, INC.

Dan Kirby appointed CCO effective February 10, 2025.
Kirby brings cell therapy commercial experience from Orca Bio, Omeros, Celgene/BMS, and Juno.
He will lead U.S. launch growth of Amtagvi and expansion of Proleukin sales.
Iovance also preparing to enter new international markets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.